Evrysdi (risdiplam) Letter of Medical Necessity
Evrysdi (risdiplam) is the oral SMA therapy. PAs require genetic confirmation, weight, and clarification on concurrent or prior SMA-modifying therapy.
FDA-Approved Indications
- ● spinal muscular atrophy in patients ≥2 months
Why Evrysdi Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Genetic confirmation missing
- 2. Concurrent SMA therapy not addressed
- 3. Weight-based dosing not specified
What to Include in a Evrysdi Letter of Medical Necessity
Document SMA genetic confirmation, type, motor function, weight, prior SMA therapies, and rationale for oral therapy.
Key clinical evidence to cite:
- ✓ FIREFISH, SUNFISH, JEWELFISH
Relevant guidelines:
- 📖 AAN SMA Guidelines
Evrysdi Prior Authorization Criteria
Standard criteria across major US payers for Evrysdi. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Documented failure or contraindication to formulary alternatives
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Evrysdi
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Evrysdi Prior Authorization FAQ
Why was my Evrysdi prior authorization denied?
The most common denial reasons for Evrysdi are: Genetic confirmation missing; Concurrent SMA therapy not addressed; Weight-based dosing not specified.
What should a Evrysdi Letter of Medical Necessity include?
Document SMA genetic confirmation, type, motor function, weight, prior SMA therapies, and rationale for oral therapy.
Which payers cover Evrysdi?
Evrysdi is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Medicare Part D, though formulary tier and prior authorization criteria vary.